Table. 2 FDA- and NMPA-approved AADs for cancer treatment.
From: Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Classification | Name of the drug | The target of action | Approved tumors for treatment | Approved time and institution |
|---|---|---|---|---|
Anti-angiogenic monoclonal antibodies | Bevacizumab | VEGFA | NSCLC/mCRC/mRCC/OVC/CC/BC/GBM | 2004 (FDA) |
Aflibercept | VEGFA/B, PIGF | mCRC | 2012 (FDA) | |
Ramucirumab | VEGFR2 | NSCLC/HCC/mCRC/GC/GEJA | 2005 (FDA) | |
Endogenous angiogenic inhibitors | Recombinant human endostatin injection | VEGF, HIF-1α, MMPs, bFGF | NSCLC | 2006 (NMPA) |
Antiangiogenic tyrosine kinase inhibitors | Sorafenib | VEGFR2/3, PDGFR-β, c-Kit, FLT-3, et al. | HCC/RCC/TC | 2005 (FDA) |
Sunitinib | VEGFR1/2/3, PDGFRα/β, Kit, FLT-3, RET, et al. | GIST/PAAD/mRCC | 2006 (FDA) | |
Pazopanib | VEGFR1/2/3, PDGFRβ, FGFR1, c-Kit. | RCC/STS | 2009 (FDA) | |
Vandetanib | VEGFR2, EGFR, RET. | Medullary TC | 2011 (FDA) | |
Axitinib | VEGFR1/2/3, PDGFRβ, c-Kit. | RCC | 2012 (FDA) | |
Regorafenib | VEGFR1/2/3, PDGFRα/β, KIT, et al. | mCRC/HCC/GIST | 2012 (FDA) | |
Ponatinib | Abl, PDGFRα, VEGFR2, FGFR1. | AML/CML | 2012 (FDA) | |
Nintedanib | VEGFR1/2/3, FGFR1/2/3, PDGFRα/β. | NSCLC | 2014 (FDA) | |
Apatinib | VEGFR2 | GC/GEJA/HCC | 2014 (NMPA) | |
Lenvatinib | VEGFR1/2/3, PDGFRα/β, FGFR1/2/3/4, FGFR1-4, Kit, RET. | HCC/EC/RCC/TC | 2015 (FDA) | |
Cabozantinib | VEGFR1/2/3, MET, RET, Kit, Axl, et al. | differentiated TC/medullary TC/HCC/RCC | 2016 (FDA) | |
Anlotinib | VEGFR, PDGFR, FGFR, c-Kit | NSCLC/STS | 2018 (NMPA) | |
Fruquintinib | VEGFR1/2/3 | mCRC | 2018 (NMPA) | |
Erdafitinib | FGFR2/3/4, PDGFRα/β, VEGFR2, RET, FLT4, Kit, et al. | UC | 2019 (FDA) | |
Tivozanib | VEGFR1/2/3, PDGFRβ, c-Kit | RCC | 2021 FDA |
